Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quinapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 16/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinapril SCHEMBL7421784 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL4359590 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL153436 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL6548496 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL29381792 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL29357257 | 1.00 | ACE (0.98) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL678447 | 0.99 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL11294979 | 0.99 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL9094436 | 0.99 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL19361887 | 0.99 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7118 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4259279-A1 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-18 | — | — | EP | claimed |
| US-20230285435-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | claimed |
| CN-116583291-A | Methods of treating metabolic disorders and cardiovascular diseases with inhibitors of inhibin subunit beta E (INHBE) | 雷杰纳荣制药公司 | 2023-08-11 | — | — | CN | claimed |
| US-20230174641-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | H LUNDBECK AS (DK) | 2023-06-08 | — | — | US | claimed |
| US-20230134521-A1 | COMPOUNDS FOR METHODS FOR PROMOTING FEMALE REPRODUCTIVE HEALTH THROUGH MEDIATION OF RENIN ANGIOTENSIN FUNCTION | SHANAHAN MICHAEL EMIL (US) | 2023-05-04 | — | — | US | claimed |
| US-20230017661-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | VERI NANO INC. (US) | 2023-01-19 | — | — | US | claimed |
| EP-0412594-A2 | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-13 | — | — | EP | claimed |
| EP-0411766-A1 | Substituted quinazolinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-06 | — | — | EP | claimed |
| EP-0409332-A2 | Substituted triazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-23 | — | — | EP | claimed |
| EP-0407102-A1 | Substituted imidazo-fused 5-membered ring heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-09 | — | — | EP | claimed |
| EP-0400974-A2 | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0401030-A2 | Angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0400835-A1 | Substituted benzimidazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0285992-A1 | Crystalline quinapril and a process for producing the same | WARNER-LAMBERT COMPANY (US) | 1988-10-12 | — | — | EP | claimed |
| US-4761479-A | HYPOTENSIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1988-08-02 | — | — | US | claimed |
| US-4743450-A | ANGIOTENSION CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1988-05-10 | — | — | US | claimed |